This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Access to cheaper alternatives and low enrollment prompted the company to remove the medicine — along with the HIV medicines Emtriva, Tybost, and Complera — from its patent assistance program next month, according to an Oct. 8 letter that announced the move and that has not been widely reported.
This exclusivity is the lifeblood of pharmaceutical innovation, allowing companies to recoup their massive R&D investments and incentivizing further research. According to a 2021 study by the Tufts Center for the Study of DrugDevelopment, the average cost to develop a new drug is a staggering $2.6
On one hand, robust IPR protection is essential to incentivise research and development. It encourages pharmaceuticalcompanies to invest heavily in discovering new drugs, developing innovative treatments, and improving healthcare outcomes. However, the flip side of the coin is equally important.
wants to ensure the ensuing the US does not lag behind other countries in drugdevelopment. We want to make sure we are getting rid of the regulatory impediments [that stop drugs getting to market],” RFK Jr stated. “It Tasos Katopodis / Stringer via Getty Images.
Despite this, Brazil’s trade protectionist policies mean that there are few pharmaceuticalcompanies of international origin within the country. There are also strict price controls, which in some cases can limit profitability for manufacturers. Brazilian public spending on healthcare, drugpricing reforms and remote medicine.
Almost 40 years since it was instituted, some have described the FDA’s orphan drug program, which is meant to foster innovation, as “ one of the most successful US legislative actions in recent history ”. However, extended market exclusivity is often associated with high drugpricing and limited patient access.
What’s more, with many key biologics scheduled to lose patent protection in this decade, Indian pharmaceuticalcompanies ought to seize this opportunity and leverage innovative technologies to introduce quality and way more affordable biosimilars in the domestic as well as global markets. appeared first on Express Pharma.
In 1983, the US Congress passed the Orphan Drug Act to encourage more pharmaceuticalcompanies to engage in R&D to develop treatments for rare diseases through the offering of financial incentives.
accelerates its crackdown on drugpricing through new legislation and regulatory enforcement, pharma companies in China, India, Japan, and South Korea are feeling the ripple effect. This article explores whats behind the sudden slump in Asian pharmaceutical equities and why U.S. As the U.S. Table of Contents The U.S.
Biden administration officials have abandoned their own proposal to require drugcompanies to disclose the prices and research costs of drugs that are driving up spending in state Medicaid programs , STAT reports. Pharmaceuticalcompanies and lobbying groups heavily pressured the U.S.
Just 9% came from the private sector, such as pharmaceuticalcompanies. Looked at another way, the public sector provided 62% of the $1.2 billion in funding, followed by philanthropies that contributed 24%. Continue to STAT+ to read the full story…
Role of HEOR in Pharmaceutical Industry With budget constraints tightening and drugprices facing greater scrutiny, Health Economics and Outcomes Research has become a cornerstone of modern pharmaceutical strategy. How Does the HEOR Model Work for PharmaceuticalCompanies?
Sit back and relax, while the article unfolds before you, the magic model that is certain to revamp your company Achieving economic sustenance and ensuring smooth sailing even in unfavorable situations are two common dreams that every pharmaceuticalcompany shares.
Patents are often described as the ‘lifeblood’ of pharmaceuticalcompanies. 1 However, patent protection for pharmaceutical products is an economic trade-off between providing monopoly rights that incentivise development of future products and permitting higher drugprices to recoup the investment.
The Inflation Reduction Act, which became US law in August 2022, has invited its fair share of critics and supporters over its drugpricing provisions. While negotiating drugprices is common practice in other major markets, CMS had not previously held the legal authority to do so.
CMS is issuing unique J-codes for 505(b)(2) drugs, classifying them as sole-source products if not therapeutically equivalent. This pathway reduces submission denial risk, accelerates drugdevelopment, and offers potential market exclusivity for up to 7 years.
These highlight the parent company’s focus on innovative and high-value drugdevelopment. Sandoz has faced and may in the future face strong competition from other generic and biosimilar pharmaceuticalcompanies, which aggressively compete for market share, including through significant price competition.
Over the past five to ten years US investors have focused on technology and internet companies, and relatively little on new biotech or pharmaceuticalcompanies.
Once again, House lawmakers have introduced a bill to alter a key provision of the Inflation Reduction Act in response to arguments that the federal law is discouraging investment in developing so-called small molecule medicines.
Now, he’s offering hope for other families facing similar hurdles through his company, Elpida Therapeutics, which is seeking to develop treatments for diseases too rare for pharmaceuticalcompanies to tackle. Read the rest…
As companies invest billions in research and development, protecting their innovations through strategic patent management has become more important than ever. This comprehensive guide will explore how pharmaceuticalcompanies can leverage their drug patent portfolios to maximize value, maintain market dominance, and drive innovation.
Today, we’re hearing more about President Trump’s “most-favored nation” plan for drugpricing, Recursion’s case for why the company laid off 20% of its staff, and more.
Impact on drugpricing and affordability Increased API costs may force some manufacturers to reduce output or exit the market entirely, reducing competition and potentially driving price inflation” Rising production costs due to tariffs could lead to higher drugprices, particularly in markets where pricing pressures are already a concern.
billion buyout of Blueprint Medicines is the sector’s second-largest M&A deal this year and represents the highest value paid for an immune drugdeveloper since April 2023. Sanofi’s $9.1 Sanofi’s $9.1 Informa PLCs registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales.
Compounded GLP-1RAs have completely disrupted pricing frameworks for Wegovy and Mounjaro, what happens now? Robert Barrie June 27, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook The list price for a month’s supply of 2.4mg Wegovy – the drug’s highest does – is $1,350 in the US, whereas the same dose in the UK costs £175.80
Good morning, pharma companies are still struggling to decide how to respond to Trump’s drugpricing policy. A Washington representative for one pharmaceuticalcompany, granted anonymity to discuss internal thinking, said the firm expects more details this week, likely on Wednesday. We discuss today.
We organize all of the trending information in your field so you don't have to. Join 11,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content